The Drugs Technical Advisory Board (DTAB), the highest authority under the Union health ministry on technical matters rejected a proposal to make amendment in the Drugs and Cosmetics Rules, 1945 demanding to sell remaining quantities of unused clinical trial batch of a biological drug within its shelf life. This came into discussion on the 68th annual meeting of DTAB which was held on 16 February. The members of the meeting said that, only after the assurance of consistency, biological products can be permitted to sell.

The proposal is to make use of the valuable drugs which is manufactured under test license for the purpose of clinical trials. Currently, as it is manufactured on a test license, it cannot be sold and remaining unused drugs will be destroyed. After the discussions, the DTAB rejected the proposal to sell remaining unused clinical trial batch of a biological drug within its shelf life. DTAB was reconstituted recently with the appointment of Dr. Jagdish Prasad, director general of health services (DGHS) as the chairman and Dr. G N Singh, Drugs Controller General (India) as one of its member secretary.

PharmaBiz

 

Other News

Additional Steps Announced by FDA to Modernize Clinical Trials

The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]

Read More

Accreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA 

This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]

Read More

BSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing

BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]

Read More

TUV SUD Inspects IVD Medical Devices’ Cyber Security

The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]

Read More

TGA Supports MHRA’s New Regulations

The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]

Read More

Medical Devices with Extended CE Certification Are Now Accepted On The UK Market

The MHRA revised its guidelines to make clear its stance and reflect its intention to extend the acceptance of CE-marked medical devices on the British market beyond June 30th, 2023. A statutory document that will […]

Read More

The NMPA Enhanced Regulation of Cosmetic Medicine

According to a representative of the State Administration for Market Regulation, after the industry’s quick development, prominent issues like unethical medical practices, fake goods, false advertising, and price fraud emerged, endangering the health and interests […]

Read More

Radiation Sterilization Master File Pilot Program Announced by CDRH

CDRH is establishing a Radiation Sterilization Master File Pilot Program to assist businesses in developing less troublesome regulatory methods for sterilizing licensed medical equipment, such as switching radiation sources. The pilot program, which is optional, […]

Read More